Survodutide: Boehringer Ingelheim's GLP-1/Glucagon Dual Agonist
Survodutide combines GLP-1 and glucagon receptor agonism. Phase 3 data expected 2026. Positioned between tirzepatide and retatrutide. Complete compound profile.
While Eli Lilly's retatrutide captures headlines as a triple agonist, Boehringer Ingelheim is pursuing a different combination: survodutide (BI 456906), a dual GLP-1/glucagon receptor agonist that adds glucagon activation without GIP engagement.
Mechanism
Survodutide activates two receptors: GLP-1 (appetite suppression, glycemic control) and glucagon (energy expenditure, hepatic fat clearance). This is the same glucagon component that retatrutide uses, but without the GIP receptor that tirzepatide and retatrutide share. The rationale: glucagon's hepatic effects may be particularly valuable for liver disease (MASH/NASH) applications.
Phase 2 Data
- Approximately 19% weight loss at 46 weeks (highest dose) in adults with obesity
- Significant reduction in liver fat content — the signal that led to prioritization of the MASH indication
- GI adverse events consistent with the GLP-1 class, plus glucagon-associated effects
Phase 3 Program
Boehringer has prioritized the MASH/NASH indication for survodutide, with Phase 3 trials underway. The obesity indication Phase 3 data is expected in 2026. Survodutide received FDA Breakthrough Therapy designation for MASH.
Competitive Positioning
| Drug | Mechanism | ~Weight Loss | Liver Focus |
|---|---|---|---|
| Semaglutide | GLP-1 | ~17% | Secondary |
| Tirzepatide | GLP-1/GIP | ~23% | Secondary |
| Survodutide | GLP-1/glucagon | ~19% | Primary (MASH) |
| Retatrutide | GLP-1/GIP/glucagon | ~28% | Trial ongoing |
Survodutide's niche may be liver disease rather than pure obesity — its glucagon component drives hepatic fat clearance more aggressively than GLP-1 mono- or dual-agonists, potentially making it the best-in-class for MASH/NASH patients who also need weight loss.
The Bottom Line
Survodutide represents the GLP-1/glucagon dual agonist approach — sharing retatrutide's glucagon component but without GIP engagement. Positioned primarily for MASH/NASH with secondary obesity application, it fills a specific gap in the incretin pipeline for liver disease patients. Phase 3 data in 2026 will determine its competitive position.
Sources
- Boehringer Ingelheim. Survodutide Phase 2 results. Clinical trial presentations.
- FDA. Breakthrough Therapy Designation for survodutide (MASH). 2025.
- ClinicalTrials.gov. NCT survodutide Phase 3 program.